1
|
Monteduro AG, Rizzato S, Caragnano G, Trapani A, Giannelli G, Maruccio G. Organs-on-chips technologies – A guide from disease models to opportunities for drug development. Biosens Bioelectron 2023; 231:115271. [PMID: 37060819 DOI: 10.1016/j.bios.2023.115271] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 11/24/2022] [Accepted: 03/26/2023] [Indexed: 04/03/2023]
Abstract
Current in-vitro 2D cultures and animal models present severe limitations in recapitulating human physiopathology with striking discrepancies in estimating drug efficacy and side effects when compared to human trials. For these reasons, microphysiological systems, organ-on-chip and multiorgans microdevices attracted considerable attention as novel tools for high-throughput and high-content research to achieve an improved understanding of diseases and to accelerate the drug development process towards more precise and eventually personalized standards. This review takes the form of a guide on this fast-growing field, providing useful introduction to major themes and indications for further readings. We start analyzing Organs-on-chips (OOC) technologies for testing the major drug administration routes: (1) oral/rectal route by intestine-on-a-chip, (2) inhalation by lung-on-a-chip, (3) transdermal by skin-on-a-chip and (4) intravenous through vascularization models, considering how drugs penetrate in the bloodstream and are conveyed to their targets. Then, we focus on OOC models for (other) specific organs and diseases: (1) neurodegenerative diseases with brain models and blood brain barriers, (2) tumor models including their vascularization, organoids/spheroids, engineering and screening of antitumor drugs, (3) liver/kidney on chips and multiorgan models for gastrointestinal diseases and metabolic assessment of drugs and (4) biomechanical systems recapitulating heart, muscles and bones structures and related diseases. Successively, we discuss technologies and materials for organ on chips, analyzing (1) microfluidic tools for organs-on-chips, (2) sensor integration for real-time monitoring, (3) materials and (4) cell lines for organs on chips. (Nano)delivery approaches for therapeutics and their on chip assessment are also described. Finally, we conclude with a critical discussion on current significance/relevance, trends, limitations, challenges and future prospects in terms of revolutionary impact on biomedical research, preclinical models and drug development.
Collapse
Affiliation(s)
- Anna Grazia Monteduro
- Omnics Research Group, Department of Mathematics and Physics "Ennio De Giorgi", University of Salento and Institute of Nanotechnology, CNR-Nanotec and INFN Sezione di Lecce, Via per Monteroni, 73100, Lecce, Italy
| | - Silvia Rizzato
- Omnics Research Group, Department of Mathematics and Physics "Ennio De Giorgi", University of Salento and Institute of Nanotechnology, CNR-Nanotec and INFN Sezione di Lecce, Via per Monteroni, 73100, Lecce, Italy
| | - Giusi Caragnano
- Omnics Research Group, Department of Mathematics and Physics "Ennio De Giorgi", University of Salento and Institute of Nanotechnology, CNR-Nanotec and INFN Sezione di Lecce, Via per Monteroni, 73100, Lecce, Italy
| | - Adriana Trapani
- Department of Pharmacy-Drug Sciences, University of Bari "Aldo Moro", Bari, Italy
| | - Gianluigi Giannelli
- National Institute of Gastroenterology IRCCS "Saverio de Bellis", Research Hospital, Castellana Grotte, Bari, Italy
| | - Giuseppe Maruccio
- Omnics Research Group, Department of Mathematics and Physics "Ennio De Giorgi", University of Salento and Institute of Nanotechnology, CNR-Nanotec and INFN Sezione di Lecce, Via per Monteroni, 73100, Lecce, Italy.
| |
Collapse
|
2
|
Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation. Int J Mol Sci 2021; 22:ijms222313090. [PMID: 34884894 PMCID: PMC8658471 DOI: 10.3390/ijms222313090] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 11/27/2021] [Accepted: 11/29/2021] [Indexed: 02/07/2023] Open
Abstract
Hepatocellular carcinoma (HCC) is a highly lethal cancer, and although a few drugs are available for treatment, therapeutic effectiveness is still unsatisfactory. New drugs are urgently needed for hepatocellular carcinoma (HCC) patients. In this context, reliable preclinical assays are of paramount importance to screen the effectiveness of new drugs and, in particular, measure their effects on HCC cell proliferation. However, cell proliferation measurement is a time-consuming and operator-dependent procedure. The aim of this study was to validate an engineered miniaturized on-chip platform for real-time, non-destructive cell proliferation assays and drug screening. The effectiveness of Sorafenib, the first-line drug mainly used for patients with advanced HCC, was tested in parallel, comparing the gold standard 96-well-plate assay and our new lab-on-chip platform. Results from the lab-on-chip are consistent in intra-assay replicates and comparable to the output of standard crystal violet proliferation assays for assessing Sorafenib effectiveness on HCC cell proliferation. The miniaturized platform presents several advantages in terms of lesser reagents consumption, operator time, and costs, as well as overcoming a number of technical and operator-dependent pitfalls. Moreover, the number of cells required is lower, a relevant issue when primary cell cultures are used. In conclusion, the availability of inexpensive on-chip assays can speed up drug development, especially by using patient-derived samples to take into account disease heterogeneity and patient-specific characteristics.
Collapse
|
3
|
Profiling Human CD55 Transgene Performance Assist in Selecting Best Suited Specimens and Tissues for Swine Organ Xenotransplantation. BIOLOGY 2021; 10:biology10080747. [PMID: 34439979 PMCID: PMC8389641 DOI: 10.3390/biology10080747] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/07/2021] [Revised: 07/28/2021] [Accepted: 07/30/2021] [Indexed: 11/17/2022]
Abstract
Simple Summary The unbalance between availability and needs of human organs has drawn researchers’ attention to xenotransplantation as an option to cope with this shortage. Pig organs have received substantial attention for being comparable to human’s; nevertheless, compatibility constrains still block clinical applications. Transgenesis of human complement regulatory proteins, including the CD55 gene and its product the decay-accelerating factor (DAF), has been proposed to overcome xenorejection. This line of research has obtained interesting results along the years; however, most works assessing the impact of this strategy for xenotransplantation are limited to analyzing gene expression and assessing resistance to conventional serum challenge hemolysis assays, which provide somewhat reduced information prior to surgery. In this work, we tried to expand the analysis of the hCD55 transgene performance beyond common practice and into a better molecular understanding of its impact in xenotransplantation. We determined hCD55 gene expression, as well as hDAF protein presence, in different organs from five transgenic pigs, comparing readings from organs worthy for transplantation and other non-valuable organs and tissues. We also assessed the ability of transgenic cells, compared to non-transgenic, to withstand hemolysis and cytolysis. Finally, we made an effort to establish potential correlations between the hCD55 mRNA and hDAF protein levels detected. Abstract Xenotransplantation of pig organs receives substantial attention for being comparable to human’s. However, compatibility constraints involving hyper-acute rejection (HAR) still block clinical applications. Transgenesis of human complement regulatory proteins has been proposed to overcome xenorejection. Pigs expressing human-CD55 have been widely tested in experimental surgery. Still, no standardized method has been developed to determine tissue expression of human decay-accelerating factor (DAF), hCD55’s product, or to predict the ability to overpass HAR. Here we describe objective procedures addressing this need. Organs and tissues from five hCD55 transgenic pigs were collected and classified according to their xenotransplantation value. The ability to overcome HAR was assessed by classical complement pathway hemolysis assays. Quantitative PCR mRNA expression and Western blot protein level studies were performed. Real-time cytotoxicity assays (RTCA) on fibroblast cultures exposed to baboon and human sera informed on longer-term rejection dynamics. While greater hCD55/DAF expression correlated with better performance, the results obtained varied among specimens. Interestingly, the individual with highest mRNA and protein levels showed positive feedback for hCD55 transcript after challenge with human and baboon sera. Moreover, hCD55 expression correlated to DAF levels in the liver, lung and intestine, but not in the heart. Moreover, we found significant correlations among valuable and non-valuable tissues. In sum, the methodology proposed allows us to characterize the hCD55 transgene functioning and performance. Moreover, the correlations found could allow us to predict hCD55/DAF expression in surrogate tissues, thus eliminating the need for direct biopsies, resulting in preservation of organ integrity before xenotransplantation.
Collapse
|
4
|
Bernardo L, Corallo L, Caterini J, Su J, Gisonni-Lex L, Gajewska B. Application of xCELLigence real-time cell analysis to the microplate assay for pertussis toxin induced clustering in CHO cells. PLoS One 2021; 16:e0248491. [PMID: 33720984 PMCID: PMC7959359 DOI: 10.1371/journal.pone.0248491] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2020] [Accepted: 02/27/2021] [Indexed: 02/06/2023] Open
Abstract
The microplate assay with Chinese Hamster Ovary (CHO) cells is currently used as a safety test to monitor the residual pertussis toxin (PT) amount in acellular pertussis antigens prior to vaccine formulation. The assay is based on the findings that the exposure of CHO cells to PT results in a concentration-dependent clustering response which can be used to estimate the amount of PT in a sample preparation. A major challenge with the current CHO cell assay methodology is that scoring of PT-induced clustering is dependent on subjective operator visual assessment using light microscopy. In this work, we have explored the feasibility of replacing the microscopy readout for the CHO cell assay with the xCELLigence Real-Time Cell Analysis system (ACEA BioSciences, a part of Agilent). The xCELLigence equipment is designed to monitor cell adhesion and growth. The electrical impedance generated from cell attachment and proliferation is quantified via gold electrodes at the bottom of the cell culture plate wells, which is then translated into a unitless readout called cell index. Results showed significant decrease in the cell index readouts of CHO cells exposed to PT compared to the cell index of unexposed CHO cells. Similar endpoint concentrations were obtained when the PT reference standard was titrated with either xCELLigence or microscopy. Testing genetically detoxified pertussis samples unspiked or spiked with PT further supported the sensitivity and reproducibility of the xCELLigence assay in comparison with the conventional microscopy assay. In conclusion, the xCELLigence RTCA system offers an alternative automated and higher throughput method for evaluating PT-induced clustering in CHO cells.
Collapse
Affiliation(s)
- Lidice Bernardo
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
- * E-mail:
| | - Lucas Corallo
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Judy Caterini
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Jin Su
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Lucy Gisonni-Lex
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| | - Beata Gajewska
- Department of Analytical Sciences, Sanofi Pasteur, Toronto, ON, Canada
| |
Collapse
|
5
|
Stefanowicz-Hajduk J, Ochocka JR. Real-time cell analysis system in cytotoxicity applications: Usefulness and comparison with tetrazolium salt assays. Toxicol Rep 2020; 7:335-344. [PMID: 32090021 PMCID: PMC7025972 DOI: 10.1016/j.toxrep.2020.02.002] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Revised: 01/31/2020] [Accepted: 02/06/2020] [Indexed: 01/08/2023] Open
Abstract
RTCA system allows to easily monitor cell adhesion and proliferation. The real-time impedance technique is widely used in many toxicological studies. RTCA results are generally comparable with results from tetrazolium salts assays. RTCA analysis should be limited when drugs with electroactive additives are tested. Tetrazolium salts assays should be avoided when colored compounds are studied.
Real-time cell analysis (RTCA) is a technique based on impedance and microsensor electrodes. RTCA system allows label-free, real-time, and continuous monitoring of cell adhesion, morphology, and rate of cell proliferation. The system offers a wide range of applications, mainly in toxicological studies, new drug screening, and microbiology. Here, we describe the usefulness of the system in different applications and compare this technology with conventional endpoint assays based on tetrazolium salts. We present advantages and disadvantages of the system and endpoint methods and their limitations in cytotoxicity investigations.
Collapse
Affiliation(s)
- Justyna Stefanowicz-Hajduk
- Department of Biology and Pharmaceutical Botany, Medical University of Gdańsk, Al. Hallera 107, 80-416, Gdańsk, Poland
| | - J Renata Ochocka
- Department of Biology and Pharmaceutical Botany, Medical University of Gdańsk, Al. Hallera 107, 80-416, Gdańsk, Poland
| |
Collapse
|
6
|
Albuz Ö, Dülger D, Tunali BÇ, Aydin F, Yalçin S, Türk M. Effects of B2O3 (boron trioxide) on colon cancer cells: our first-step experience and in vitro results. ACTA ACUST UNITED AC 2019; 43:209-223. [PMID: 31320819 PMCID: PMC6620035 DOI: 10.3906/biy-1901-34] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Boron oxide (B2O3) is derived from dehydration of boric acid and is a colorless, semitransparent, crystalline compound that is moderately soluble in water. On the other hand, boron oxide is chemically hygroscopic. This gives the molecule the ability to soak up water and adhere to tissues. Boron oxide can be used locally after tumor debulking in inoperable tumors and especially when the tumor-free margin distance cannot be provided. For all these reasons we aimed to evaluate the in vitro test results of B2O3 in terms of cytotoxicity, genotoxicity, apoptosis, and necrotic effects on L929 fibroblast cells and DLD-1 colorectal adenocarcinoma cells. Our studies demonstrated that boron oxide compounds appear to be highly cytotoxic for both cell lines according to WST cell viability assay (44.22% and 18.36% on DLD-1 and L929, respectively). Although no genotoxic effects were observed, boron oxide compounds showed antiproliferative effects for both cell lines. The prepared boron oxide compounds may hold the potential to be applied locally to the remaining tissue after surgery and further research and evaluation will be needed to determine its effectiveness.
Collapse
Affiliation(s)
- Özgür Albuz
- Department of General Surgery, Keçiören Training and Research Hospital, Ankara, Turkey
| | - Dilek Dülger
- Department of Medical Microbiology of Basic Medical Sciences, Faculty of Medicine, Karabük University, Karabük, Turkey
| | - Beste Çağdaş Tunali
- Department of Bioengineering, Faculty of Engineering, Kırıkkale University, Kırıkkale, Turkey
| | - Feray Aydin
- Department of General Surgery, 29 Mayıs State Hospital, Ankara, Turkey
| | - Selim Yalçin
- Department of Oncology, Faculty of Medicine, Kırıkkale University, Kırıkkale, Turkey
| | - Mustafa Türk
- Department of Bioengineering, Faculty of Engineering, Kırıkkale University, Kırıkkale, Turkey
| |
Collapse
|
7
|
Detection of apoptotic and live pre-osteoblast cell line using impedance-based biosensors with variable electrode design. Biosens Bioelectron 2019; 128:37-44. [PMID: 30616216 DOI: 10.1016/j.bios.2018.11.057] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2018] [Revised: 11/22/2018] [Accepted: 11/23/2018] [Indexed: 01/03/2023]
Abstract
Electrical impedance-based sensing of cell activity has become a powerful analytical tool that allows the monitoring of several relevant biological processes associated with cell evolution and morphology. In these types of biosensors, the electrode design has a direct impact on the sensitivity because it defines the capability of the biosensor to measure small changes in the impedance resulting from cell activities. Herein, impedance-based biosensors arrays with several configurations were successfully developed and used to study the impact of the electrode layout on the dynamics of cultured pre-osteoblast cells. The biosensor design was initially validated by measuring the effect of electrode design on the capacitance of a dielectric polymer (parylene) that mimics the dielectric characteristics of cell populations, results are shown in the Supplementary information section. Results from in vitro cell growth indicate that the optimized design of single electrodes with a diameter of 50 µm, are the most sensitive to cell motion whereas increasing the number of electrodes allows clear differentiation between living and dead cells after 3 h of inducing apoptosis. Apoptosis death was induced with Staurosporine, a chemical mediator of apoptosis in osteoblasts. These impedance results have been validated with optical imaging and flow cytometry analysis that were performed on parallel cultures. Frequency and electrolyte concentration effects are also discussed.
Collapse
|
8
|
Lebourgeois S, Fraisse A, Hennechart-Collette C, Guillier L, Perelle S, Martin-Latil S. Development of a Real-Time Cell Analysis (RTCA) Method as a Fast and Accurate Method for Detecting Infectious Particles of the Adapted Strain of Hepatitis A Virus. Front Cell Infect Microbiol 2018; 8:335. [PMID: 30319992 PMCID: PMC6167467 DOI: 10.3389/fcimb.2018.00335] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2018] [Accepted: 08/30/2018] [Indexed: 11/26/2022] Open
Abstract
Hepatitis A virus (HAV) is one of the most common agents causing acute liver disease worldwide. HAV has been increasingly reported as the cause of foodborne disease outbreaks. The standard method currently available for detection of the genome of HAV in vulnerable foodstuffs is by RT-qPCR (ISO 15216). Despite its usefulness in the investigation of foodborne viruses, the use of RT-qPCR in food virology has been shown to overestimate the quantity of infectious virus or to highly underestimate the effect of the treatment on virus inactivation. The gold standard methods currently used for evaluating the efficacy of inactivation treatments on the adapted strain of HAV (HM175/18f) are either the plaque assay or the end-point dilution assay (TCID50). However, both assays are labor-intensive and time-consuming. The aim of this study was to evaluate the use of the xCELLigence real-time cell analysis (RTCA) system for detecting the infectivity of the adapted strain of HAV. Kinetics of cell impedance showed that HAV induced a decrease in cell index (CI) correlated with the onset of HAV-induced cell death. In addition, the time to which the HAV-induced CI drop occurred was dependent on the viral concentration. An inverse linear relation could be established over a range of 5 log10 between the concentration of HAV and the time to reach 50% of CI decrease (TCI50), showing that the RTCA assay could be used as a titration method for HAV. In addition, the RTCA-based assay could be performed in less than 6 days instead of 12 to 14 days with the gold standard methods. Therefore, the RTCA-based titration method is a powerful and suitable tool for high-throughput screening of anti-viral treatments. Its usefulness in HAV inactivation studies will improve the assessment of viral risk in food virology, as controlling transmission of viruses through their removal from foodstuffs is also an important challenge in reducing the burden of viral foodborne illnesses.
Collapse
Affiliation(s)
- Samuel Lebourgeois
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Audrey Fraisse
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | | | - Laurent Guillier
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Sylvie Perelle
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| | - Sandra Martin-Latil
- Laboratory for Food Safety, Université Paris Est, ANSES, Maisons-Alfort, France
| |
Collapse
|
9
|
Tóth G, Szöllősi J, Vereb G. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response. Cytometry A 2017; 91:1021-1029. [DOI: 10.1002/cyto.a.23247] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2017] [Revised: 08/13/2017] [Accepted: 09/02/2017] [Indexed: 01/01/2023]
Affiliation(s)
- Gábor Tóth
- Department of Biophysics and Cell Biology; University of Debrecen; Debrecen Hungary
| | - János Szöllősi
- Department of Biophysics and Cell Biology; University of Debrecen; Debrecen Hungary
- MTA-DE Cell Biology and Signaling Research Group, Faculty of Medicine; University of Debrecen; Debrecen Hungary
| | - György Vereb
- Department of Biophysics and Cell Biology; University of Debrecen; Debrecen Hungary
- MTA-DE Cell Biology and Signaling Research Group, Faculty of Medicine; University of Debrecen; Debrecen Hungary
- Faculty of Pharmacy; University of Debrecen; Debrecen Hungary
| |
Collapse
|
10
|
García-Reina A, Rodríguez-García MJ, Ramis G, Galián J. Real-time cell analysis and heat shock protein gene expression in the TcA Tribolium castaneum cell line in response to environmental stress conditions. INSECT SCIENCE 2017; 24:358-370. [PMID: 26678377 DOI: 10.1111/1744-7917.12306] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 08/11/2015] [Indexed: 06/05/2023]
Abstract
The rust red flour beetle, Tribolium castaneum (Herbst, 1797) (Coleoptera: Tenebrionidae), is a pest of stored grain and one of the most studied insect model species. Some of the previous studies involved heat response studies in terms of survival and heat shock protein expression, which are regulated to protect other proteins against environmental stress conditions. In the present study, we characterize the impedance profile with the xCELLigence Real-Time Cell Analyzer and study the effect of increased temperature in cell growth and viability in the cell line BCIRL-TcA-CLG1 (TcA) of T. castaneum. This novel system measures cells behavior in real time and is applied for the first time to insect cells. Additionally, cells are exposed to heat shock, increased salinity, acidic pH and UV-A light with the aim of measuring the expression levels of Hsp27, Hsp68a, and Hsp83 genes. Results show a high thermotolerance of TcA in terms of cell growth and viability. This result is likely related to gene expression results in which a significant up-regulation of all studied Hsp genes is observed after 1 h of exposure to 40 °C and UV light. All 3 genes show similar expression patterns, but Hsp27 seems to be the most affected. The results of this study validate the RTCA method and reveal the utility of insect cell lines, real-time analysis and gene expression studies to better understand the physiological response of insect cells, with potential applications in different fields of biology such as conservation biology and pest management.
Collapse
Affiliation(s)
- Andrés García-Reina
- Department of Zoology and Physical Anthropology, University of Murcia, Campus Mare Nostrum, E-30100, Murcia, Spain
| | | | - Guillermo Ramis
- Department of Animal Production, Faculty of Veterinary, University of Murcia, Campus Mare Nostrum, E-30100, Murcia, Spain
| | - José Galián
- Department of Zoology and Physical Anthropology, University of Murcia, Campus Mare Nostrum, E-30100, Murcia, Spain
| |
Collapse
|
11
|
Screening, verification, and analysis of biomarkers for drug-induced cardiac toxicity in vitro based on RTCA coupled with PCR Array technology. Toxicol Lett 2017; 268:17-25. [PMID: 28099878 DOI: 10.1016/j.toxlet.2017.01.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Revised: 01/11/2017] [Accepted: 01/13/2017] [Indexed: 12/23/2022]
Abstract
Cardiotoxicity is one of the most serious side effects of new drugs. Early detection of the drug induced cardiotoxicity based on the biomarkers provides an important preventative strategy for detecting potential cardiotoxicity of candidate drugs. In this study, we aim to identify the predictive genomics biomarkers for drug-induced cardiac toxicity based on the RTCA coupled with PCR Array technology in primary cells. Three prototypical cardiotoxic compounds (doxorubicin, isoproterenol, ouabain) with different mechanisms were firstly real-time monitored to diagnose the cytotoxicity by using the RTCA, while the functional alterations of cardiomyocytes were also monitored by analyzing the beating frequency of cardiomyocytes. Then cardiac specific toxicity gene expression changes were studied by using the technology of PCR Array, which can detect the changes of 84 cardiac functions related genes. Rps6kb1 was identified to be the common cardiac biomarkers by using multivariate statistical and integration analyses. The biomarker was further verified by selecting other drugs with or without cardiotoxicity, and the results showed that the gene exhibited specific changes in cardiac toxicity. Moreover, IPA was applied to combine relevant pathways of Rps6kb1, and identify the main types of cardiac toxicity. These results would further enrich the evaluating strategy of drug-induced cardiotoxicity in vitro, and Rps6kb1 could be used as the specific biomarker of cardiotoxcity during safety assessment of the novel drug candidates.
Collapse
|
12
|
Reuse of E-plate cell sensor arrays in the xCELLigence Real-Time Cell Analyzer. Biotechniques 2016; 61:117-22. [PMID: 27625205 DOI: 10.2144/000114450] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 06/16/2016] [Indexed: 11/23/2022] Open
Abstract
The xCELLigence Real-Time Cell Analyzer (RTCA) is a non-invasive, impedence-based biosensor system that can measure cell viability, migration, growth, spreading, and proliferation. Changes in cell morphology and behavior are continuously monitored in real time using microelectronics located in the wells of RTCA E-plates. According to the manufacturer's recommendation, E-plates are single-use and disposable. Here, we show that E-plates can be regenerated and reused several times without significantly effecting experimental results.
Collapse
|
13
|
Messina W, Fitzgerald M, Moore E. SEM and ECIS Investigation of Cells Cultured on Nanopillar Modified Interdigitated Impedance Electrodes for Analysis of Cell Growth and Cytotoxicity of Potential Anticancer Drugs. ELECTROANAL 2016. [DOI: 10.1002/elan.201600025] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Walter Messina
- Tyndall National Institute; University College Cork; Cork Republic Of Ireland
- University College Cork, Dept. Of Chemistry; Cork Republic Of Ireland
| | - Michelle Fitzgerald
- Tyndall National Institute; University College Cork; Cork Republic Of Ireland
| | - Eric Moore
- Tyndall National Institute; University College Cork; Cork Republic Of Ireland
- University College Cork, Dept. Of Chemistry; Cork Republic Of Ireland
| |
Collapse
|
14
|
Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight 2016; 1. [PMID: 27453950 DOI: 10.1172/jci.insight.87059] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
DC vaccination with autologous tumor lysate has demonstrated promising results for the treatment of glioblastoma (GBM) in preclinical and clinical studies. While the vaccine appears capable of inducing T cell infiltration into tumors, the effectiveness of active vaccination in progressively growing tumors is less profound. In parallel, a number of studies have identified negative costimulatory pathways, such as programmed death 1/programmed death ligand 1 (PD-1/PD-L1), as relevant mediators of the intratumoral immune responses. Clinical responses to PD-1 pathway inhibition, however, have also been varied. To evaluate the relevance to established glioma, the effects of PD-1 blockade following DC vaccination were tested in intracranial (i.c.) glioma tumor- bearing mice. Treatment with both DC vaccination and PD-1 mAb blockade resulted in long-term survival, while neither agent alone induced a survival benefit in animals with larger, established tumors. This survival benefit was completely dependent on CD8+ T cells. Additionally, DC vaccine plus PD-1 mAb blockade resulted in the upregulation of integrin homing and immunologic memory markers on tumor-infiltrating lymphocytes (TILs). In clinical samples, DC vaccination in GBM patients was associated with upregulation of PD-1 expression in vivo, while ex vivo blockade of PD-1 on freshly isolated TILs dramatically enhanced autologous tumor cell cytolysis. These findings strongly suggest that the PD-1/PD-L1 pathway plays an important role in the adaptive immune resistance of established GBM in response to antitumor active vaccination and provide us with a rationale for the clinical translation of this combination therapy.
Collapse
Affiliation(s)
- Joseph P Antonios
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Horacio Soto
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Richard G Everson
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Joey Orpilla
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Diana Moughon
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Namjo Shin
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Shaina Sedighim
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - William H Yong
- Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Gang Li
- Department of Biostatistics, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Timothy F Cloughesy
- Brain Research Institute, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center (JCCC), David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Department of Neurology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Linda M Liau
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Brain Research Institute, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center (JCCC), David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| | - Robert M Prins
- Department of Neurosurgery, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Brain Research Institute, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Jonsson Comprehensive Cancer Center (JCCC), David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, UCLA, Los Angeles, California, USA
| |
Collapse
|
15
|
WYGANOWSKA-SWIATKOWSKA MARZENA, KOTWICKA MALGORZATA, URBANIAK PAULINA, NOWAK AGNIESZKA, SKRZYPCZAK-JANKUN EWA, JANKUN JERZY. Clinical implications of the growth-suppressive effects of chlorhexidine at low and high concentrations on human gingival fibroblasts and changes in morphology. Int J Mol Med 2016; 37:1594-600. [DOI: 10.3892/ijmm.2016.2550] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Accepted: 04/06/2016] [Indexed: 11/05/2022] Open
|
16
|
Differential Effects of β-Blockers, Angiotensin II Receptor Blockers, and a Novel AT2R Agonist NP-6A4 on Stress Response of Nutrient-Starved Cardiovascular Cells. PLoS One 2015; 10:e0144824. [PMID: 26691397 PMCID: PMC4686716 DOI: 10.1371/journal.pone.0144824] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 11/24/2015] [Indexed: 12/18/2022] Open
Abstract
In order to determine differences in cardiovascular cell response during nutrient stress to different cardiovascular protective drugs, we investigated cell responses of serum starved mouse cardiomyocyte HL-1 cells and primary cultures of human coronary artery vascular smooth muscles (hCAVSMCs) to treatment with β-blockers (atenolol, metoprolol, carvedilol, nebivolol, 3μM each), AT1R blocker losartan (1μM) and AT2R agonists (CGP42112A and novel agonist NP-6A4, 300nM each). Treatment with nebivolol, carvedilol, metoprolol and atenolol suppressed Cell Index (CI) of serum-starved HL-1 cells (≤17%, ≤8%, ≤15% and ≤15% respectively) as measured by the Xcelligence Real-Time Cell Analyzer (RTCA). Conversely, CI was increased by Ang II (≥9.6%), CGP42112A (≥14%), and NP-6A4 (≥25%) respectively and this effect was blocked by AT2R antagonist PD123319, but not by AT1R antagonist losartan. Thus, the CI signature for each drug could be unique. MTS cell proliferation assay showed that NP-6A4, but not other drugs, increased viability (≥20%) of HL-1 and hCAVSMCs. Wheat Germ Agglutinin (WGA) staining showed that nebivolol was most effective in reducing cell sizes of HL-1 and hCAVSMCs. Myeloid Cell Leukemia 1 (MCL-1) is a protein critical for cardiovascular cell survival and implicated in cell adhesion. β-blockers significantly suppressed and NP-6A4 increased MCL-1 expression in HL-1 and hCAVSMCs as determined by immunofluorescence. Thus, reduction in cell size and/or MCL-1 expression might underlie β-blocker-induced reduction in CI of HL-1. Conversely, increase in cell viability and MCL-1 expression by NP-6A4 through AT2R could have resulted in NP-6A4 mediated increase in CI of HL-1. These data show for the first time that activation of the AT2R-MCL-1 axis by NP-6A4 in nutrient-stressed mouse and human cardiovascular cells (mouse HL-1 cells and primary cultures of hCAVSMCs) might underlie improved survival of cells treated by NP-6A4 compared to other drugs tested in this study.
Collapse
|
17
|
Tang W, Song H, Cai W, Shen X. Real Time Monitoring of Inhibition of Adipogenesis and Angiogenesis by (-)-Epigallocatechin-3-Gallate in 3T3-L1 Adipocytes and Human Umbilical Vein Endothelial Cells. Nutrients 2015; 7:8871-86. [PMID: 26516907 PMCID: PMC4632457 DOI: 10.3390/nu7105437] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 09/30/2015] [Indexed: 01/17/2023] Open
Abstract
Little is known about the effect of (−)-epigallocatechin-3-gallate (EGCG) on angiogenesis in adipocytes. We aimed to test the effect of EGCG on the expression of vascular endothelial growth factor (VEGF) in adipocytes. The levels of VEGF secretion, the expression of VEGF message ribonucleic acid (mRNA) and VEGF protein in 3T3-L1 cells were measured by enzyme linked immunosorbent assay (ELISA), real time polymerase chain reaction (PCR), and immunofluorescence staining, respectively. The xCELLigence real time cell analysis system was used to study the growth and differentiation of 3T3-L1 preadipocytes. A coculture system was used to test the effects of 3T3-L1 cells on proliferation of human umbilical vein endothelial cells (HUVECs). The conditioned media derived from 3T3-L1 cells treated with or without EGCG was used to culture the HUVECs for a tube formation assay. Peroxisome proliferator-activated receptor γ (PPARγ) and CCAAT/enhancer binding protein α (C/EBPα), two transcription factors related to both adipogenesis and angiogenesis, were examined to explore the potential mechanism. We found that all the three measurements of VEGF expression in adipocytes (mRNA, protein and secretion in media) were reduced after EGCG treatment. The growth of HUVECs co-cultured with 3T3-L1 cells was significantly increased and the conditioned media from EGCG treated 3T3-L1 adipocytes inhibited tube formation in HUVECs. Both PPARγ and C/EBPα expression in adipocytes were decreased with EGCG treatment. In conclusion, findings from this study suggest that EGCG may inhibit angiogenesis by regulating VEGF expression and secretion in adipocytes.
Collapse
Affiliation(s)
- Wenjing Tang
- Department of Clinical Nutrition, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
- Department of Nutrition, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
| | - Huanlei Song
- Department of Clinical Nutrition, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
| | - Wei Cai
- Department of Clinical Nutrition, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
- Department of Nutrition, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
| | - Xiuhua Shen
- Department of Clinical Nutrition, Xin Hua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200092, China.
- Department of Nutrition, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China.
| |
Collapse
|
18
|
Procházka E, Escher BI, Plewa MJ, Leusch FDL. In Vitro Cytotoxicity and Adaptive Stress Responses to Selected Haloacetic Acid and Halobenzoquinone Water Disinfection Byproducts. Chem Res Toxicol 2015; 28:2059-68. [DOI: 10.1021/acs.chemrestox.5b00283] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Affiliation(s)
- Erik Procházka
- Smart
Water Research Centre, Australian Rivers Institute, School of Environment, Griffith University, Gold Coast, Queensland 4222, Australia
| | - Beate I. Escher
- Smart
Water Research Centre, Australian Rivers Institute, School of Environment, Griffith University, Gold Coast, Queensland 4222, Australia
- Cell
Toxicology, Helmholtz Centre for Environmental Research−UFZ, 04318 Leipzig, Germany
- Environmental
Toxicology, Center for Applied Geosciences, Eberhard Karls University Tübingen, 72074 Tübingen, Germany
| | | | - Frederic D. L. Leusch
- Smart
Water Research Centre, Australian Rivers Institute, School of Environment, Griffith University, Gold Coast, Queensland 4222, Australia
| |
Collapse
|
19
|
Everson RG, Antonios JP, Lisiero DN, Soto H, Scharnweber R, Garrett MC, Yong WH, Li N, Li G, Kruse CA, Liau LM, Prins RM. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma. Neuro Oncol 2015; 18:368-78. [PMID: 26330563 DOI: 10.1093/neuonc/nov153] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2015] [Accepted: 07/11/2015] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Immunotherapy is an ideal treatment modality to specifically target the diffusely infiltrative tumor cells of malignant gliomas while sparing the normal brain parenchyma. However, progress in the development of these therapies for glioblastoma has been slow due to the lack of immunogenic antigen targets that are expressed uniformly and selectively by gliomas. METHODS We utilized human glioblastoma cell cultures to induce expression of New York-esophageal squamous cell carcinoma (NY-ESO-1) following in vitro treatment with the demethylating agent decitabine. We then investigated the phenotype of lymphocytes specific for NY-ESO-1 using flow cytometry analysis and cytotoxicity against cells treated with decitabine using the xCelligence real-time cytotoxicity assay. Finally, we examined the in vivo application of this immune therapy using an intracranially implanted xenograft model for in situ T cell trafficking, survival, and tissue studies. RESULTS Our studies showed that treatment of intracranial glioma-bearing mice with decitabine reliably and consistently induced the expression of an immunogenic tumor-rejection antigen, NY-ESO-1, specifically in glioma cells and not in normal brain tissue. The upregulation of NY-ESO-1 by intracranial gliomas was associated with the migration of adoptively transferred NY-ESO-1-specific lymphocytes along white matter tracts to these tumors in the brain. Similarly, NY-ESO-1-specific adoptive T cell therapy demonstrated antitumor activity after decitabine treatment and conferred a highly significant survival benefit to mice bearing established intracranial human glioma xenografts. Transfer of NY-ESO-1-specific T cells systemically was superior to intracranial administration and resulted in significantly extended and long-term survival of animals. CONCLUSION These results reveal an innovative, clinically feasible strategy for the treatment of glioblastoma.
Collapse
Affiliation(s)
- Richard G Everson
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Joseph P Antonios
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Dominique N Lisiero
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Horacio Soto
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Rudi Scharnweber
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Matthew C Garrett
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - William H Yong
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Ning Li
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Gang Li
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Carol A Kruse
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Linda M Liau
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| | - Robert M Prins
- Department of Neurosurgery, University of California Los Angeles, Los Angeles, California (R.G.E., J.P.A., D.N.L., H.S., R.S., M.C.G., C.A.K., L.M.L., R.M.P.); Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California (D.N.L., R.M.P.); Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California (W.H.Y.); Department of Biostatistics, University of California Los Angeles, Los Angeles, California (N.L., G.L.); Brain Research Institute, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.); Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, University of California Los Angeles, Los Angeles, California (C.A.K., L.M.L., R.M.P.)
| |
Collapse
|
20
|
Kiely M, Hodgins SJ, Merrigan BA, Tormey S, Kiely PA, O'Connor EM. Real-time cell analysis of the inhibitory effect of vitamin K2 on adhesion and proliferation of breast cancer cells. Nutr Res 2015; 35:736-43. [PMID: 26082424 DOI: 10.1016/j.nutres.2015.05.014] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2014] [Revised: 05/12/2015] [Accepted: 05/27/2015] [Indexed: 11/19/2022]
Abstract
Breast cancer is the most prevalent cancer type worldwide. Continued efforts to improve treatment strategies for patients with breast cancer will be instrumental in reducing the death rates associated with this disease. In particular, the triple-negative breast cancer subtype of breast cancer has no targeted therapy available so it is essential to continue to work on any potential therapies. Vitamin K (VK) is known for its essential role in the clotting cascade. The antitumor properties of VK derivatives have been reported in both hepatocellular carcinoma and glioblastoma. Our hypothesis was that menaquinone-4, the most common form of vitamin K2 (VK2), is an effective anticancer agent against breast cancer cell types. In this study, we used a novel impedance-based live cell monitoring platform (xCELLigence) to determine the effects of VK derivatives on the triple-negative breast cancer cell line, MDA-MB-231, and the HER2+ breast cancer cell line, MDA-MB-453. Cells were treated with varying concentrations of menaquinone-4 (VK2) previously reported to have an antiproliferative effect on human glioblastoma cells. After initial testing, these concentrations were adjusted to 100, 125, and 150 μmol/L. A significant dose-dependent, growth inhibitory effect was found when cells were treated at these concentrations. These effects were seen in both adhesion and proliferation phases and show a dramatic reduction in cell growth. Additional analysis of MDA-MB-231 cells treated with VK2 (100 μmol/L) in combination with a low-glucose nutrient media showed a further decrease in adhesion and viability. This is the first study of its kind showing the real-time effects of VK derivatives on breast cancer cells and suggests that dietary factors may be an important consideration for patients.
Collapse
Affiliation(s)
- Maeve Kiely
- Department of Life Sciences, University of Limerick, Limerick, Ireland; Materials and Surface Science Institute, University of Limerick, Limerick, Ireland; Stokes Institute, University of Limerick, Limerick, Ireland
| | - Spencer J Hodgins
- Graduate Entry Medical School, University of Limerick, Limerick, Ireland
| | - B Anne Merrigan
- Department of Surgery, University Hospital Limerick, Limerick, Ireland
| | - Shona Tormey
- Graduate Entry Medical School, University of Limerick, Limerick, Ireland; Department of Surgery, University Hospital Limerick, Limerick, Ireland
| | - Patrick A Kiely
- Department of Life Sciences, University of Limerick, Limerick, Ireland; Materials and Surface Science Institute, University of Limerick, Limerick, Ireland; Stokes Institute, University of Limerick, Limerick, Ireland
| | | |
Collapse
|
21
|
Downregulation of ABCE1 via siRNA affects the sensitivity of A549 cells against chemotherapeutic agents. Med Oncol 2015; 32:103. [PMID: 25744244 DOI: 10.1007/s12032-015-0557-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2015] [Accepted: 02/27/2015] [Indexed: 01/28/2023]
Abstract
ATP-binding cassette E1 (ABCE1) is involved in several biological functions in cancer cells such as tumor proliferation, antiapoptotic pathway and chemoresistance mechanism. This work aimed to investigate the alterations in chemosensitivity of A549 lung cancer cells for 5-Fluorouracil (5-FU) and irinotecan by silencing ABCE1 using specific small interfering RNAs (siRNA). The cells were treated with low doses of drugs, alone and also their combinations with ABCE1 siRNA. Cytotoxicity, cell proliferation and apoptosis/necrosis evaluations were performed in order to examine the effects of the combined treatment. Reverse transcriptase polymerase chain reaction (RT-PCR) was used to confirm the downregulation of ABCE1. We also investigated the levels of B cell lymphoma 2 (Bcl-2) and mammalian target of rapamycin (mTOR) after the treatments by RT-PCR. Downregulation of ABCE1 improved the anticancer effects of 5-FU in inducing cell viability/proliferation inhibition and apoptosis/necrosis, whereas interestingly, almost did not change or slightly reduced the anticancer effects of irinotecan. ABCE1 expression significantly decreased by transfecting the cells with ABCE1 siRNA. Moreover, Bcl-2 and mTOR levels changed after the single or combined therapy in parallel with the apoptotic and antiproliferation effect. In conclusion, the simultaneous treatment of lung cancer cells with ABCE1 siRNA and 5-FU exhibited synergistic or additive effects; however, ABCE1 siRNA and irinotecan had unexpected antagonistic effects. Our findings demonstrate that the strategy of downregulation of ABCE1 may be included in conventional 5-FU chemotherapy for lung cancer, minimizing the usage of 5-FU at high dosages.
Collapse
|
22
|
Caviglia C, Zór K, Montini L, Tilli V, Canepa S, Melander F, Muhammad HB, Carminati M, Ferrari G, Raiteri R, Heiskanen A, Andresen TL, Emnéus J. Impedimetric toxicity assay in microfluidics using free and liposome-encapsulated anticancer drugs. Anal Chem 2015; 87:2204-12. [PMID: 25582124 DOI: 10.1021/ac503621d] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
In this work, we have developed a microfluidic cytotoxicity assay for a cell culture and detection platform, which enables both fluid handling and electrochemical/optical detection. The cytotoxic effect of anticancer drugs doxorubicin (DOX), oxaliplatin (OX) as well as OX-loaded liposomes, developed for targeted drug delivery, was evaluated using real-time impedance monitoring. The time-dependent effect of DOX on HeLa cells was monitored and found to have a delayed onset of cytotoxicity in microfluidics compared with static culture conditions based on data obtained in our previous study. The result of a fluorescent microscopic annexin V/propidium iodide assay, performed in microfluidics, confirmed the outcome of the real-time impedance assay. In addition, the response of HeLa cells to OX-induced cytotoxicity proved to be slower than toxicity induced by DOX. A difference in the time-dependent cytotoxic response of fibrosarcoma cells (HT1080) to free OX and OX-loaded liposomes was observed and attributed to incomplete degradation of the liposomes, which results in lower drug availability. The matrix metalloproteinase (MMP)-dependent release of OX from OX-loaded liposomes was also confirmed using laryngopharynx carcinoma cells (FaDu). The comparison and the observed differences between the cytotoxic effects under microfluidic and static conditions highlight the importance of comparative studies as basis for implementation of microfluidic cytotoxic assays.
Collapse
Affiliation(s)
- Claudia Caviglia
- Department of Micro- and Nanotechnology, Technical University of Denmark , DK-2800 Kongens Lyngby, Denmark
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. Biosci Rep 2014; 34:BSR20140031. [PMID: 24935351 PMCID: PMC4114067 DOI: 10.1042/bsr20140031] [Citation(s) in RCA: 69] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
Increasing our knowledge of the mechanisms regulating cell proliferation, migration and invasion are central to understanding tumour progression and metastasis. The local tumour microenvironment contributes to the transformed phenotype in cancer by providing specific environmental cues that alter the cells behaviour and promotes metastasis. Fibroblasts have a strong association with cancer and in recent times there has been some emphasis in designing novel therapeutic strategies that alter fibroblast behaviour in the tumour microenvironment. Fibroblasts produce growth factors, chemokines and many of the proteins laid down in the ECM (extracellular matrix) that promote angiogenesis, inflammation and tumour progression. In this study, we use a label-free RTCA (real-time cell analysis) platform (xCELLigence) to investigate how media derived from human fibroblasts alters cancer cell behaviour. We used a series of complimentary and novel experimental approaches to show HCT116 cells adhere, proliferate and migrate significantly faster in the presence of media from human fibroblasts. As well as this, we used the xCELLigence CIM-plates system to show that HCT116 cells invade matrigel layers aggressively when migrating towards media derived from human fibroblasts. These data strongly suggest that fibroblasts have the ability to increase the migratory and invasive properties of HCT116 cells. This is the first study that provides real-time data on fibroblast-mediated migration and invasion kinetics of colon cancer cells.
Collapse
|